| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.05. | Reviva Pharmaceuticals GAAP EPS of -$0.46 misses by $0.11 | 1 | Seeking Alpha | ||
| 13.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 13.05. | Reviva Pharmaceuticals: Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | 260 | GlobeNewswire (Europe) | - Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 6 | SEC Filings | ||
| 15.04. | Reviva Pharmaceuticals sichert sich 10 Mio. US-Dollar und verlängert finanzielle Reichweite bis Q1 2027 | 1 | Investing.com Deutsch | ||
| 15.04. | Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 | 1 | Investing.com | ||
| 15.04. | Reviva Pharmaceuticals: Reviva Announces Letter to Shareholders | 516 | GlobeNewswire (Europe) | CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies... ► Artikel lesen | |
| 15.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | Reviva Pharmaceuticals: Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | 338 | GlobeNewswire (Europe) | - Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia - - Current data package highlights... ► Artikel lesen | |
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 28.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 25.03. | Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split | 2 | Insider Monkey | ||
| 25.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering | 164 | GlobeNewswire (Europe) | CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that... ► Artikel lesen | |
| 23.03. | Reviva Pharmaceuticals raises $10 million in public offering | 1 | Investing.com | ||
| 23.03. | Reviva Pharmaceuticals schließt Kapitalerhöhung über 10 Millionen US-Dollar ab | 4 | Investing.com Deutsch | ||
| 19.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 19.03. | Reviva Pharmaceuticals prices $10M public offering at $1.50 | 3 | Investing.com | ||
| 19.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 18.03. | Reviva Pharmaceuticals announces proposed public offering | 1 | Seeking Alpha |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 35,560 | +2,48 % | Bayer, MustGrow Biologics, K+S - die geheime Gewinnformel hinter der biologischen Dünger-Revolution | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die globale Düngemittelbranche durchläuft ihren bedeutendsten Strukturwandel seit Generationen. Steigende Weltbevölkerung, technologische... ► Artikel lesen | |
| NOVO NORDISK | 37,535 | +3,13 % | Novo Nordisk Aktie: Jetzt oder nie! | © Foto: SHVETS production auf Pexels (Symbolbild)Wer Novo Nordisk in den letzten Monaten beobachtet hat, kennt das Auf und Ab dieser Aktie. Der dänische Pharmakonzern, jahrelang gefeierter Star der... ► Artikel lesen | |
| ROCHE | 356,03 | +5,21 % | Aktien Europa: Leichte Verluste - fragile Waffenruhe im Iran mahnt zur Vorsicht | PARIS/LONDON/ZÜRICH (dpa-AFX) - Die europäischen Aktienmärkte haben am Donnerstag leicht nachgegeben. Die fragile Waffenruhe im Iran-Krieg sorgte für Zurückhaltung. So hatte das US-Militär nahe der... ► Artikel lesen | |
| VIATRIS | 13,720 | +2,24 % | Dividendenbekanntmachungen (22.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,78 USD 0,6712 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0645 EUR ADVANCED ENERGY INDUSTRIES... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,740 | +2,43 % | Green Thumb Industries: Marijuana Meme Stock or Dream Stock? | ||
| TONIX PHARMACEUTICALS | 10,400 | +5,76 % | Tonix Pharmaceuticals legt Daten zur Opioid-Nutzung bei Fibromyalgie vor | ||
| NEWRON PHARMACEUTICALS | 14,050 | +6,44 % | Millionen-Liefervertrag für den deutschen Markt: Bioxyne Limited meldet operativen Durchbruch | ||
| FILANA THERAPEUTICS | 1,200 | +2,56 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,190 | +1,27 % | Lifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with Oramed | HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| COMPASS PATHWAYS | 11,300 | +3,67 % | Wall Street entdeckt Psychedelika - steht Emyria vor einer Neubewertung? | ||
| ACHIEVE LIFE SCIENCES | 4,620 | +8,96 % | ACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report | ||
| OPUS GENETICS | 3,800 | +4,40 % | Opus Genetics, Inc.: Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts | ||
| AURINIA PHARMACEUTICALS | 14,070 | +4,18 % | Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy | ||
| NRX PHARMACEUTICALS | 3,555 | +1,86 % | Morning Market Movers: Sadot Group, Laser Photonics, Gorilla Technology Group, NRx Pharmaceuticals See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 11,310 | -4,07 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen |